Market Report, "Chile Pharmaceuticals & Healthcare Report Q1 2016", published

Chile's rising rates of drug approvals, combined with its increasing reliance on foreign medicines, will continue to provide significant appeal to multinational drugmakers over the long-term. The increasing number of new pharmaceuticals in the Chilean market will remain driven by the country's growing epidemiological burden, which will continue to benefit commercial opportunity as drug access grows .

Headline Expenditure Projections

Pharmaceuticals: From CLP1,948bn (USD4.0bn) in 2014 to CLP2,093bn (USD3.30bn) in 2015; +7.5% in local currency terms and -17.7% in US dollar terms. Forecast unchanged from Q 315 .
Healthcare: From CLP11,154bn (USD19.54bn) in 2014 to CLP12,072bn (USD19.01bn) in 2015; +8.2% in local currency terms and -2.7% in US dollar terms. Forecast broadly unchanged from Q315 .

Full Report Details at
- http://www.fastmr.com/prod/1082734_chile_pharmaceuticals.aspx?afid=301

Risk/Reward Index

In BMI's Q415 Risk Reward Index, Chile remains in sixth place out of the 18 markets in the Americas matrix with a slightly improved score of 53.9 out of 100; up from 52.7 in Q315. President Bachelet's centre-left government will increasingly focus on improving Chile's regulatory framework, placing an emphasis on raising standards for quality assurance compliance potentially raising operating costs.

Key Trends And Developments

Drug approvals have steadily increased in recent years with the total percentage of new drug rejections falling from 40% in 2007 to 8% in 2013, allowing pharmaceutical approvals to rise from 60% to 92% over the same period. In terms of therapy areas, between 2007 and 2013, oncology drugs accounted for the largest percentage of new molecules introduced to the Chilean market, spiking in 2013 as the approval of new oncology drugs accounted for one-third of all new drug approvals.

The Chile Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Chile Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Chile pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Chile, to test other views - a key input for successful budgeting and strategic business planning in the Chilean pharmaceutical and healthcare market.
* Target business opportunities and risks in the Chilean pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Chile.
* Assess the activities, strategy and market position of your competitors

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Saudi Arabia Pharmaceuticals & Healthcare Report Q1 2016
- Kenya Pharmaceuticals & Healthcare Report Q1 2016
- Ukraine Pharmaceuticals & Healthcare Report Q1 2016
- Thailand Pharmaceuticals & Healthcare Report Q1 2016
- Oman Pharmaceuticals & Healthcare Report Q1 2016